未知生产厂商
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Reglixane is an agonist of peroxisome proliferator-activated receptor (PPAR) gamma and alpha.
For the treatment of diabetes mellitus type 1 and 2.
